Anna M. Varghese

14.9k total citations · 1 hit paper
111 papers, 2.6k citations indexed

About

Anna M. Varghese is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anna M. Varghese has authored 111 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Oncology, 39 papers in Cancer Research and 36 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anna M. Varghese's work include Pancreatic and Hepatic Oncology Research (40 papers), Cancer Genomics and Diagnostics (38 papers) and Colorectal Cancer Treatments and Studies (20 papers). Anna M. Varghese is often cited by papers focused on Pancreatic and Hepatic Oncology Research (40 papers), Cancer Genomics and Diagnostics (38 papers) and Colorectal Cancer Treatments and Studies (20 papers). Anna M. Varghese collaborates with scholars based in United States, India and United Kingdom. Anna M. Varghese's co-authors include Eileen M. O’Reilly, Kenneth H. Yu, Marc Ladanyi, Gregory J. Riely, Alice T. Shaw, Jeffrey A. Engelman, Mark M. Awad, Mari Mino–Kenudson, Michael F. Berger and Maeve A. Lowery and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Anna M. Varghese

101 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

2013 460 citations Anna M. Varghese, Gregory J. Riely et al. Clinical Cancer Research profile →

Peers

Anna M. Varghese

ONCOL

PRM

SURGE

Petros Christopoulos Germany

Helena Linardou Greece

Ammar Sukari United States

Yoshitaka Honma Japan

Sreenivasa Nattam United States

Kosei Hasegawa Japan

Hira Rizvi United States

Antonio Frassoldati Italy

Vera Gorbounova Russia

Petros Christopoulos Germany

Anna M. Varghese

1.4k ×0.8

ONCOL

1.2k ×1.2

PRM

688 ×1.0

529 ×0.8

216 ×0.7

SURGE

Citations per year, relative to Anna M. Varghese Anna M. Varghese (= 1×) peers Petros Christopoulos

Countries citing papers authored by Anna M. Varghese

Since Specialization

Citations

This map shows the geographic impact of Anna M. Varghese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna M. Varghese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna M. Varghese more than expected).

Fields of papers citing papers by Anna M. Varghese

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna M. Varghese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna M. Varghese. The network helps show where Anna M. Varghese may publish in the future.

Co-authorship network of co-authors of Anna M. Varghese

This figure shows the co-authorship network connecting the top 25 collaborators of Anna M. Varghese. A scholar is included among the top collaborators of Anna M. Varghese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna M. Varghese. Anna M. Varghese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Le, Dung T., Anna M. Varghese, Marcus Smith Noel, et al.. (2026). Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer. Journal for ImmunoTherapy of Cancer. 14(1). e011284–e011284.

Park, Won, Anna M. Varghese, Kenneth H. Yu, et al.. (2024). 1504MO Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum. Annals of Oncology. 35. S922–S922. 2 indexed citations

Lim, Kian‐Huat, Kristen Spencer, Rachael A. Safyan, et al.. (2024). Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205).. Journal of Clinical Oncology. 42(16_suppl). 4140–4140. 9 indexed citations

Aviki, Emeline, T. Peter Kingham, Eileen M. O’Reilly, et al.. (2024). Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer. JCO Oncology Practice. 21(9). 1325–1334. 2 indexed citations

Keane, Fergus, Richard Tuli, Catherine O’Connor, et al.. (2024). Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights.. Journal of Clinical Oncology. 42(16_suppl). 4174–4174.

Chou, Joanne F., Marinela Capanu, Jennifer Park, et al.. (2024). Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication. Pancreatology. 24(4). 608–615. 2 indexed citations

Keane, Fergus, Joanne F. Chou, Henry Walch, et al.. (2024). Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. JNCI Journal of the National Cancer Institute. 116(9). 1429–1438. 2 indexed citations

Ecker, Brett L., Quisette P. Janssen, Henry Walch, et al.. (2023). Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 29(7). 1368–1374. 13 indexed citations

Keane, Fergus, Fiyinfolu Balogun, Catherine O’Connor, et al.. (2023). Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).. Journal of Clinical Oncology. 41(4_suppl). 685–685. 1 indexed citations

10.

Tuli, Richard, Fergus Keane, Joshua D. Schoenfeld, et al.. (2023). A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.. Journal of Clinical Oncology. 41(16_suppl). 4164–4164. 1 indexed citations

11.

Keane, Fergus, Joshua D. Schoenfeld, Catherine O’Connor, et al.. (2023). A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC).. Journal of Clinical Oncology. 41(4_suppl). 725–725. 1 indexed citations

12.

Yu, Kenneth H., Jennifer Park, Ghassan K. Abou‐Alfa, et al.. (2022). Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Cancer. 128(15). 2958–2966. 7 indexed citations

13.

Park, Wungki, Catherine O’Connor, Chaitanya Bandlamudi, et al.. (2022). Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice. Clinical Cancer Research. 28(21). 4782–4792. 13 indexed citations

14.

McIntyre, Caitlin A., Sharon Lawrence, Allison L. Richards, et al.. (2020). Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer. 126(17). 3939–3949. 49 indexed citations

15.

Varghese, Anna M., Dana B. Cardin, Al B. Benson, et al.. (2020). Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. Clinical Cancer Research. 26(7). 1555–1562. 13 indexed citations

16.

Hayashi, Akimasa, Aslihan Yavas, Caitlin A. McIntyre, et al.. (2020). Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. Modern Pathology. 33(9). 1822–1831. 40 indexed citations

17.

Bendell, Johanna C., Anna M. Varghese, David M. Hyman, et al.. (2018). A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clinical Cancer Research. 24(14). 3253–3262. 81 indexed citations

18.

Mondaca, Sebastián, Walid K. Chatila, ‬David D. B. Bates, et al.. (2018). FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. Clinical Colorectal Cancer. 18(1). e39–e52. 18 indexed citations

19.

Varghese, Anna M., Maureen F. Zakowski, Helena A. Yu, et al.. (2014). Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes. Journal of Thoracic Oncology. 9(6). 892–896. 102 indexed citations

20.

Varghese, Anna M., Camelia S. Sima, Jamie E. Chaft, et al.. (2012). Lungs Don’t Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers. Journal of Thoracic Oncology. 8(1). 123–125. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact